AKEBIA THERAPEUTICS INC (AKBA)

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 204 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The firm's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The firm utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Company Info

AKEBIA THERAPEUTICS INC

245 First Street

Cambridge MASSACHUSETTS 02142

P: 16178712098

CEO: John P. Butler

Employees: 204

Website: https://akebia.com/